---
title: "Neuropsychiatric therapeutics biotech Seaport Therapeutics files for a $100 million IPO"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/282391687.md"
description: "Seaport Therapeutics, a Boston-based biotech firm focused on neuropsychiatric therapies, has filed for a $100 million IPO with the SEC. The company is developing oral treatments for conditions like depression and anxiety using its proprietary Glyph platform. Its lead programs include GlyphAllo for major depressive disorder and GlyphAgo for generalized anxiety disorder. Founded in 2024, Seaport plans to list on Nasdaq under the symbol SPTX, with Goldman Sachs and others as joint bookrunners."
datetime: "2026-04-10T21:37:29.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/282391687.md)
  - [en](https://longbridge.com/en/news/282391687.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/282391687.md)
generator: "portal-rs"
---

# Neuropsychiatric therapeutics biotech Seaport Therapeutics files for a $100 million IPO

Seaport Therapeutics, a Phase 2 biotech developing therapies for neuropsychiatric indications, filed on Friday with the SEC to raise up to $100 million in an initial public offering.

Seaport Therapeutics is a clinical-stage biotechnology company developing oral therapies for neuropsychiatric disorders, including depression, anxiety, and other central nervous system conditions. The company uses its proprietary Glyph platform, a lymphatic-targeting prodrug technology designed to improve oral bioavailability and reduce first-pass metabolism, to reformulate clinically validated mechanisms into differentiated product candidates. Its lead programs include GlyphAllo in Phase 2b for major depressive disorder and GlyphAgo in Phase 1 for generalized anxiety disorder, with additional preclinical candidates targeting depressive and related CNS disorders.

The Boston, MA-based company was founded in 2024 and plans to list on the Nasdaq under the symbol SPTX. Seaport Therapeutics filed confidentially on November 21, 2025. Goldman Sachs, J.P. Morgan, Leerink Partners, Citi, and Stifel are the joint bookrunners on the deal.

### Related Stocks

- [SEELQ.US](https://longbridge.com/en/quote/SEELQ.US.md)
- [SBIO.US](https://longbridge.com/en/quote/SBIO.US.md)
- [IBB.US](https://longbridge.com/en/quote/IBB.US.md)
- [LABU.US](https://longbridge.com/en/quote/LABU.US.md)
- [IBBQ.US](https://longbridge.com/en/quote/IBBQ.US.md)
- [BIB.US](https://longbridge.com/en/quote/BIB.US.md)
- [XBI.US](https://longbridge.com/en/quote/XBI.US.md)
- [VHT.US](https://longbridge.com/en/quote/VHT.US.md)
- [FBT.US](https://longbridge.com/en/quote/FBT.US.md)
- [SEEL.US](https://longbridge.com/en/quote/SEEL.US.md)
- [PSTV.US](https://longbridge.com/en/quote/PSTV.US.md)
- [XLV.US](https://longbridge.com/en/quote/XLV.US.md)
- [PBE.US](https://longbridge.com/en/quote/PBE.US.md)
- [CNSY.US](https://longbridge.com/en/quote/CNSY.US.md)

## Related News & Research

- [Plus Therapeutics GAAP EPS of -$1.31 misses by $0.45; reaffirms FY outlook](https://longbridge.com/en/news/296058426.md)
- [LIVE MARKETS-BofA clients flock to tech stocks](https://longbridge.com/en/news/296383193.md)
- [SBIO: U.S. Programmatic and EMEA drove 49% of Q2 sales, with margins rising to 61% and profitability expected in H2 2026](https://longbridge.com/en/news/296517769.md)
- [Guotai Asset Management sees liquidity boost driving China biotech, innovation drug shares higher](https://longbridge.com/en/news/296448906.md)
- [Moderna surges on trial win for cancer shot; William Blair upgrades](https://longbridge.com/en/news/296370751.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**